Scientists used CRISPR to disable the NRF2 gene, restoring chemotherapy sensitivity in lung cancer cells and slowing tumor ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the best gene-editing stocks to buy according to hedge funds. On November 11, ...

Crispr Therapeutics (CRSP) quickly rose 1.3% amid some takeover speculation. Crispr (CRSP) is said to have attracted takeover ...

CRISPR has turned a simple fungus into a fast-growing, meat-like protein source with impressively low environmental impact.

An experimental gene-editing treatment shows promise for permanently lowering levels of cholesterol and triglycerides, ...

By reactivating a long-lost gene, researchers were able to lower uric acid levels and stop damaging fat accumulation in human ...

The patient who was hospitalized after receiving Intellia Therapeutics’ CRISPR therapy nex-z has died. | The patient who was ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

In a major step forward for cancer care, researchers at ChristianaCare's Gene Editing Institute have shown that disabling the ...

Promising results from a small clinical trial highlight a growing interest in designing gene-editing treatments for common ...

CRISPR Therapeutics AG is rated a Buy with $1.9B cash, prudent management, and undervalued shares. Learn more about CRSP ...

Learn more about whether Aurinia Pharmaceuticals Inc. or CRISPR Therapeutics AG is a better investment based on AAII's A+ ...